Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T cell–redirecting cancer immunotherapies. The company discovers and develops therapies that target tumor-specific peptides presented by HLA molecules, with programs spanning T cell receptor (TCR)–based therapeutics, adoptive cell therapies, and bispecific molecules. Immatics was founded in 2000 and has major operations in Tübingen, Germany, and Houston, Texas. The company is publicly traded on Nasdaq under the ticker IMTX. In 2023, Immatics reported total revenue of approximately €78 million. The company employs roughly 500 people.
Verified Email Pattern
{first}.{last}@immatics.com
j****@immatics.com
j****@immatics.com
Find a verified email at Immatics
Look up any prospect by name, or by name and company, across 110M contacts.
Employees Directory
Showing 5 of 5 employees with verified contact records
| Name | Location | Verified Email |
|---|---|---|
|
|
j****@immatics.com
|
|
|
|
j****@immatics.com
|
|
|
|
j****@immatics.com
|
|
|
|
m****@immatics.com
|
|
|
|
s****@immatics.com
|
Protected by reCAPTCHA. Google Privacy Policy and Terms of Service apply.